ADVANZ Pharma corporate information

04.10.24 ADVANZ PHARMA releases its 2023-2024 ESG report reinforcing its commitment to sustainability.The report is structured across our three strategic ESG pillars: focusing on patients' needs; ensuring sustainable and responsible operations and growth; and developing our people. London, UK - 04/10/2024: - ADVANZ PHARMA Holdco Limited ("ADVANZ PHARMA" or "the Company"), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital and rare disease medicines in Europe, Canada, and Australia, is pleased to announce the release of its latest Environmental, Social & Governance (ESG) report, outlining ADVANZ PHARMA's ongoing dedication to environmental stewardship, social responsibility and ethical practices. This report is an interim update following last year's comprehensive statement. Key achievements highlighted in the report include: Focusing on patients' needs: With its medicines, ADVANZ PHARMA has reached ~236m patients from May 2023 to April 2024. In its mission to improve patients' lives, ADVANZ PHARMA continues to undertake various activities focused on providing new or enhanced treatment options and holistic support to patients and healthcare professionals (HCPs). Ensuring sustainable and responsible operations and growth: In 2023, the company has decreased its Scope 2 (market-based) emissions by 51% by moving to renewable energy contracts and undertaken a climate scenario analysis to identify climate-related risks and opportunities. The company is also actively engaging with its suppliers on ESG topics and performance against ESG metrics is a criterion in the selection process of new contract manufacturing organisations. Developing our people: We are proud to see the progress we are making on our people and culture journey, achieving a 50% representation of women across the organisation in 2023 and the launch of a new Talent development strategy and training programme. The overall employee engagement score remains very high at 89%. Steffen Wagner, CEO of ADVANZ PHARMA, said, "Sustainability and patient-centricity will remain key for ADVANZ PHARMA as we drive positive change and make a difference in the lives of patients around the world." The release of ADVANZ PHARMA's latest ESG report reinforces the company's transparency and accountability in pursuing its ESG goals.

01.09.23 ADVANZ PHARMA releases its 2022-2023 ESG report highlighting its sustained progress on environmental, social, and governance topics.The report is structured across the three key pillars that are closely linked with the Company's strategic priorities: focusing on patients' needs; ensuring sustainable and responsible operations and growth; and developing our people.ADVANZ PHARMA has committed to quantitative targets related to carbon emissions, supplier engagement, and gender balance in the workforce. London, UK - 01/09/2023: - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital and rare disease medicines in Europe, Canada, and Australia, is pleased to announce the release of its latest Environmental, Social & Governance (ESG) report, outlining ADVANZ PHARMA's dedication to environmental stewardship, social responsibility, and ethical practices. The 2022-2023 ESG report reflects ADVANZ PHARMA's continuous effort to enhance its ESG performance across all areas of its operations. Over the past year, the company has been reshaping its sustainability strategy, resulting in its ESG roadmap being managed across three key pillars: Focusing on patients' needsEnsuring sustainable, responsible operationsGrowing and developing our people Key achievements highlighted in the report include: Focusing on patients' needs: In its mission to improve patients' lives, ADVANZ PHARMA undertakes various activities focused on providing new or enhanced treatment options and holistic support to patients and healthcare professionals. ADVANZ PHARMA has also recently joined the AMR Industry Alliance to collaborate on finding sustainable solutions to curb antimicrobial resistance and support the appropriate use of antibiotics. Ensuring sustainable and responsible operations and growth: The company is focusing this year on conducting a comprehensive review of its environmental footprint. The target of halving its Scopes 1 and 2 (market-based) emissions by 2030 versus the 2022 baseline1 has been set. The company is also working on its Scope 3 baseline to lay the foundation for future commitments and actively engaging with supply chain partners on this topic (already 70% in volume) and on ESG more broadly. Developing our people: As a certified Great Place to work®, ADVANZ PHARMA was delighted to be ranked among the UK's best workplaces for wellbeing in 2022. To further foster and promote gender diversity, the company aims to have women represented in 40% to 60% of the C-suite (achieved), leadership and management by 2030. Steffen Wagner, CEO of ADVANZ PHARMA, said, "Our ESG roadmap is closely linked with our strategic priorities and growth journey, putting patients' needs and our people even more at the core while reinforcing the resilience and sustainability of our business. This reshaped ESG strategy is guided by our purpose - improving patients' lives by providing specialty, hospital and rare disease medicines they depend on - and our core values - entrepreneurship, speed and integrity." The release of ADVANZ PHARMA's latest ESG report reinforces the company's commitment, transparency, and accountability in pursuing its ESG goals. The full ESG report can be found below. 1 Baseline to be adjusted upon transformative M&A (including a full year impact of the ex-US Intercept acquisition)

Read our latest brochure to find out more about our company and our commitment to patients.

Watch our corporate video for a summary on how we work to uphold our values of entrepreneurship, speed and integrity.